Clinical Trials List
Protocol NumberYO45758
Active
2025-08-01 - 2030-12-31
Phase I
Recruiting2
ICD-10D49.9
Neoplasm of unspecified behavior of unspecified site
ICD-9239.9
Neoplasm of unspecified nature, site unspecified
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/01
Investigators and Locations
Co-Principal Investigator
- James Chih-Hsin Yang Division of Hematology & Oncology
- 吳宗哲 Division of General Internal Medicine
- 廖斌志 Division of Hematology & Oncology
- JIN-YUAN SHIH Division of General Internal Medicine
- 許嘉林 Division of General Internal Medicine
- Kun-Huei Yeh Division of Hematology & Oncology
- 吳尚俊 Division of Hematology & Oncology
- 蔡子修 Division of General Internal Medicine
- 楊景堯 Division of General Internal Medicine
- Jih-Hsiang Lee Division of General Internal Medicine
- 陳國興 Division of Hematology & Oncology
- 廖唯昱 Division of General Internal Medicine
- SHIH-HUNG YANG Division of Hematology & Oncology
- 梁逸歆 Division of Hematology & Oncology
- YEN-TING LIN Division of Hematology & Oncology
- 徐偉勛 醫學研究部
- CHAO-CHI HO CHAO-CHI HO Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 劉奕廷 Division of Hematology & Oncology
- 鍾秉軒 Division of Hematology & Oncology
- Shang-Yin Wu Division of Hematology & Oncology
- Chia-Jui Yen Division of Hematology & Oncology
- 黃盈慈 Division of Hematology & Oncology
- 陳柏全 Division of General Surgery
- Peng-Chan Lin Division of Hematology & Oncology
- Po-Wen Lin Division of General Surgery
- 黃怡菁 Division of Hematology & Oncology
- 黃怡璇 Division of Hematology & Oncology
- Chun-Hui Lee Division of Hematology & Oncology
- Shang-Hung Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
345 participants
